Recent News

Reuters reported Tuesday that the U.S. Food and Drug Administration declined to approve Cingulate’s ADHD drug. The decision is a narrow regulatory event, but it belongs in a wider public-trust story. ADHD treatment sits at the intersection of families, schools, physicians, insure

The pause on Trump’s $1.8 billion anti-weaponization fund shows why state-power abuses cannot be answered with a politically controlled payout machine.

A planned U.S.-backed Ebola quarantine facility in Kenya triggered protests and a court pause, exposing the trust deficit behind cross-border public-health logistics.

Florida’s lawsuit against OpenAI pushes AI safety out of the abstract and into product liability, parental trust, and platform incentives.

A new FDA approval for Shionogi’s COVID-prevention pill lands in a public-health environment where implementation trust matters as much as scientific clearance.

Nvidia’s new AI PC chip is not just a product launch. It is a move to make the personal computer the next control point for autonomous agents.

Europe’s move to curb U.S. cloud giants in strategic tenders is a reminder that sovereignty now runs through servers, contracts and procurement rules.

Blue Origin’s reported New Glenn explosion came just as national-security launch commitments were moving forward, raising a basic accountability question about public dependence on private space contractors.

Promising pancreatic cancer drug data is a hopeful story, but it also exposes the public-trust problem inside a healthcare system where access, evidence, and bureaucracy move at different speeds.

Pope Leo’s fresh warning about artificial intelligence is a reminder that the real political fight is over attention, authority, and who trains the systems mediating daily life.